Stock Price, News, Quote and Profile of DAVITA INC(NYSE:DVA) stock

DAVITA INC

NYSE:DVA (12/20/2024, 8:06:08 PM)

After market: 151.85 0 (0%)

151.85

+4.31 (+2.92%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryHealth Care Providers & Services

GICS SubIndustryHealth Care Services

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%-4.58%

Sales Q2Q%4.56%

CRS83.11

6 Month7.41%

Overview

Earnings (Last)10-29 2024-10-29/amc

Earnings (Next)02-11 2025-02-11/amc

Ins Owners4.09%

Inst Owners50.63%

Market Cap12.45B

Shares82.00M

PE17.1

Fwd PE13.34

Dividend YieldN/A

Analysts67.69

Short Float %8.96%

Short Ratio4.81

IPO10-31 1995-10-31

Stock Screener Links

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

DaVita, Inc. engages in the provision of medical care services. The company is headquartered in Denver, Colorado and currently employs 70,000 full-time employees. The firm is a provider of kidney care services in the United States. Its United States dialysis and related lab services (U.S. dialysis) business treats patients with chronic kidney failure, end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and also includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. The company also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.